Anzeige
Mehr »
Login
Montag, 13.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Die 1 Billionen Dollar Mine: Power Nickels Weg zur globalen Dominanz!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
143 Leser
Artikel bewerten:
(0)

Tenneco: Global Aftermarket Veteran John Perrin Appointed Vice President, General Manager of DRiV EMEA

Finanznachrichten News

KONTICH, Belgium, Jan. 13, 2025 (GLOBE NEWSWIRE) -- John Perrin, a highly respected business leader with decades of experience with Tenneco and in the global aftermarket, has been appointed Vice President and General Manager of the DRiV EMEA business. He will be based in DRiV's European headquarters in Kontich, Belgium.

DRiV is one of the world's premier partners to replacement parts distributors and wholesalers, engine rebuilders and vehicle service and repair businesses. The business offers an unparalleled portfolio of more than 30 elite brands, including Monroe®, MOOG®, FERODO®, Wagner, Champion®, and Walker®. DRiV employs more than 9,000 team members worldwide.

Perrin, who began his career in 1996 as an aftermarket Territory Sales Manager for Tenneco, has advanced through an impressive series of increasingly responsible positions over the past 28 years. Most recently, he served Tenneco as Vice President, Office of Strategic Execution, Americas Commercial Growth. Additional executive roles have included Business Line Leader - Chassis; Executive Director, Marketing, Product and Engineering, North America Aftermarket; and Director, Strategic Accounts.

"John has the ideal background to lead the DRiV EMEA team in accelerating product innovation and value creation for businesses and individuals at every level of the automotive and commercial vehicle aftermarkets," said DRiV President Chintan Sopariwala. "Given his deep experience in sales, marketing, product development and operations, he understands the challenges and tremendous opportunities ahead for aftermarket businesses. And John, like everyone on our team, is laser focused on helping customers achieve new levels of success in every category we serve."

Perrin joins DRiV EMEA as the business rolls out several important initiatives, including the launch of an all-new line of Wagner Sensors, the introduction of comprehensive new product ranges under the Monroe and Walker brands, and the deployment of leading-edge digital resources in support of engine professionals who rely on DRiV's Engine Expertise brands - AE®, FP Diesel®, Glyco®, Goetze®, Nüral®, and Payen®.

"DRiV is built to make bold moves, and I look forward to helping our customers leverage the full value of our growing brand, product, distribution and technical support capabilities," Perrin said. "Our commitment to customer-focused innovation is transforming every area of our business, from research and product development to the way we package our products, to the technical assistance, training and marketing support we provide to our business partners."

About Tenneco

Tenneco is one of the world's leading designers, manufacturers, and marketers of automotive products for original equipment and aftermarket customers. Through our DRiV, Performance Solutions, Clean Air and Powertrain business groups, Tenneco is driving advancements in global mobility by delivering technology solutions for light vehicle, commercial truck, off-highway, industrial, motorsport and the aftermarket.

Visit www.tenneco.comto learn more.

CONTACT:
Simonetta Esposito
Global Communications
Tenneco
sesposito@driv.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ad1d5018-78ac-4f16-b86c-39fd6b71a1e0


© 2025 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.